Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False
2022-09-14
财报
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false.
It is understood that Fosun has sought confirmation from regulatory authorities through multiple channels. The China Banking and Insurance Regulatory Commission (CBIRC) has not asked commercial banks to check about their financial exposure on Fosun, and many commercial banks that cooperate with Fosun have never received relevant notices.
Gong Ping, Executive President and CFO of Fosun International, said, "Fosun's recent seemingly frequent reductions in shareholdings and divestments are a continuation of its financial strategy of balancing investment and divestment in the past few years. Fosun has been dynamically sorting and optimizing its asset portfolios. Such moves are not just for coping with the current market environment. However, we noticed that the complex external environment has raised public opinion on the disposal of the Group's assets, resulting in a one-sided interpretation of such asset disposal, while neglecting the Group's general principle of asset optimization, which is our long-term dynamic asset optimization."
According to the interim results announced on 30 August, Fosun's four major business segments of Health, Happiness, Wealth, and Intelligent Manufacturing demonstrated resilience. In the first half of the year, Fosun achieved sustainable revenue growth, its total revenue reached RMB82.89 billion, representing a year-on-year increase of 17.7%. Its enterprise operation profit increased by 35.5% year-on-year. Meanwhile, the Group's funds remained stable. As at the end of the reporting period, cash, bank balances and term deposits were abundant, amounting to RMB117.65 billion; the adjusted NAV remained stable at HK$24.2 per share.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。